Skip to main content
. Author manuscript; available in PMC: 2021 Sep 11.
Published in final edited form as: J Bone Miner Res. 2018 May 22;33(8):1450–1463. doi: 10.1002/jbmr.3440

Fig. 6.

Fig. 6.

Systemic delivery of CXCR3 antagonist (AMG-487) reduces bone loss in vivo. (A) Representative radiographic images of control (ctrl), P.g.-LPS + veh injections and P.g.-LPS + AMG-487. Note the reduction in alveolar bone (in between the first and second molars) in the P.g.-LPS + veh group. (B) Graph representing the averaged bone levels in control (Ctrl), P.g.-LPS + veh injections and P.g.-LPS + AMG-487 groups. (C) Graph representing normalized bone loss (control group subtracted) in P.g.-LPS + veh injections and P.g.-LPS + AMG-487 groups. For both graphs (B, C), significance was compared using a Student’s t test. n ≥ 5 mice/group, p ≤ 0.05*, p ≤ 0.01**, p ≤ 0.001***. Data represented as mean ± standard error of the mean (SEM). (D) Hematoxylin and eosin (H&E)-stained slides of control (Ctrl), P.g.-LPS + veh injections and P.g.-LPS + AMG-487 groups. Note the increased cellular infiltrates in the P.g.-LPS + veh injection group (yellow arrow). 20× magnification.